Best Biotech Stocks Worth Watching – November 7th

Moderna, Natera, AbbVie, Amgen, and Regeneron Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biological science to develop products such as medicines, vaccines, and diagnostic tests. For investors, they can offer growth potential but are often volatile because a company’s prospects may depend on clinical-trial results, regulatory approvals, and successful commercialization. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of NASDAQ:MRNA traded up $12.73 during midday trading on Friday, reaching $254.19. The company’s stock had a trading volume of 16,295,043 shares, compared to its average volume of 18,981,452. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average of $191.85 and a 200 day moving average of $91.51. Moderna has a twelve month low of $22.28 and a twelve month high of $267.50. The firm has a market capitalization of $101.48 billion, a PE ratio of -31.81 and a beta of 1.16.

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NASDAQ NTRA traded down $53.09 during midday trading on Friday, reaching $310.67. 5,775,619 shares of the stock were exchanged, compared to its average volume of 1,603,151. The firm has a market cap of $44.78 billion, a price-to-earnings ratio of -272.52 and a beta of 1.55. Natera has a twelve month low of $181.00 and a twelve month high of $437.41. The firm has a 50-day simple moving average of $380.25 and a two-hundred day simple moving average of $269.68.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV traded up $3.27 on Friday, reaching $291.51. The stock had a trading volume of 5,039,501 shares, compared to its average volume of 5,346,511. AbbVie has a 12-month low of $190.75 and a 12-month high of $302.93. The business’s 50-day moving average price is $271.98 and its two-hundred day moving average price is $239.04. The company has a market cap of $515.03 billion, a P/E ratio of 50.17, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20.

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Shares of Amgen stock traded up $0.14 during trading hours on Friday, reaching $460.42. The stock had a trading volume of 2,579,312 shares, compared to its average volume of 2,619,150. The stock’s 50 day moving average is $422.43 and its 200 day moving average is $378.19. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen has a twelve month low of $312.39 and a twelve month high of $483.99. The firm has a market capitalization of $248.92 billion, a PE ratio of 26.71, a PEG ratio of 3.41 and a beta of 0.43.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

NASDAQ REGN traded up $1.45 during trading hours on Friday, reaching $904.35. The company’s stock had a trading volume of 1,122,229 shares, compared to its average volume of 793,479. The firm has a market capitalization of $93.11 billion, a price-to-earnings ratio of 19.97, a P/E/G ratio of 1.51 and a beta of 0.10. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The company’s 50-day moving average is $804.38 and its two-hundred day moving average is $742.81.